ESC Heart Fail June 2023 PMID 36967133

Systematic review of sodium-glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure-related events.

Buena Aziri, Edin Begic, Slobodan Jankovic, Zorica Mladenovic, Bojan Stanetic, Tamara Kovacevic-Preradovic, Amer Iglica, Aida Mujakovic

Full text PDF Download social card

Mentions

Peak: 2 in Jun 2023

across 3 sources since Mar 2023

Extended reach

8,430

potential audience

Total likes

Video views

Mentions per month

Mar 2023 – Aug 2023

Where it's discussed

X / Twitter4 posts
News2 articles
YouTube1 videos

AI synopsis

What people are saying

The overall sentiment reflects cautious optimism, with comments describing the review as a 'hopeful prospect' and emphasizing its potential to improve heart failure outcomes. Words like 'significant' and phrases about 'lowering hospitalization' indicate that readers see this publication as a meaningful contribution to medical research, though engagement remains moderate with references to specific trials and implications.

AgreementModerate agreement

Most posts express positive views of the article, emphasizing the promising nature of SGLT2 inhibitors for heart failure treatment.

InterestModerate interest

Discussions show moderate curiosity, with expressions like 'hopeful prospect' and recognition of the article's significance.

EngagementModerate engagement

The conversations include mentions of the methods and implications, reflecting a fair level of engagement.

ImpactModerate impact

Posts suggest that the article could influence clinical approaches or future research, indicating a moderate impact.

Abstract in brief

Sodium-glucose cotransporter 2 (SGLT2) inhibitors play a vital role in treating heart failure by promoting glucose excretion and reducing reabsorption.
A systematic review examined 12 randomized controlled trials involving a total of 83,878 patients, focusing on various SGLT2 inhibitors like canagliflozin, dapagliflozin, and empagliflozin.
Findings indicate SGLT2 inhibitors significantly lower the odds of heart failure hospitalization and related cardiovascular issues, highlighting their effectiveness in improving heart failure outcomes.

Read the full abstract

All mentions

SGLT2 Inhibitors in Heart Failure Treatment: A Systematic Review

A systematic review examined 12 RCTs involving 83,878 patients on SGLT2 inhibitors like canagliflozin, dapagliflozin, and empagliflozin. Findings indicate these drugs significantly reduce heart failure hospitalizations…

Social RTCL TV · Aug 17, 2023 92 views

Satoru Mitsuboshi

@3stars67664378 · X

Jun 2, 2023 · 1 share · 1,798 followers View post →

ぽん@

@pharma_pon · X

Jun 2, 2023 · 8 likes · 1 share · 985 followers View post →

QxMD | Your Personalized Medical Journal

@QxMD · X

Systematic review of sodium-glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure-related events. Journal: ESC Heart Failure https://t.co/S9NA57rvZx

May 8, 2023 · 5,547 followers View post →

Bojan Stanetic

@StaneticBojan · X

Systematic review of sodium‐glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure‐related events https://t.co/HNYAjgiGuR

Mar 27, 2023 · 5 followers View post →